5H-呋喃并[3,2-g]色烯类化合物的合成及其抗肿瘤活性

目的 设计合成5H-呋喃并[3,2-g]色烯类化合物,并测定其体外抗肿瘤活性。方法 以2’,4’-二羟基苯乙酮为原料,经缩合、催化氢化和 Fries 重排等反应合成目标化合物。采用人骨肉瘤细胞U2OS-EGFP-4A12G对目标化合物的体外抗肿瘤活性进行初步评价。结果与结论 合成了10个未见文献报道的5H-呋喃并[3,2-g]色烯类化合物,其结构经红外光谱、质谱、核磁共振氢谱确证。化合物7a、7e 和 7h 对人骨肉瘤细胞 U2OS-EGFP-4A12G 的抑制活性较强,其IC₅₀值分别为16.53、7.74、13.27 μmol·L^-1。5H-呋喃并[3,2-g]色烯类化合物是一类具有新型骨架结构的抗肿瘤化合物,值得进一步研究。     

8-氟-2,3-二氢喹啉-4(1H)-酮缩氨基脲类化合物的设计、合成及抗真菌活性研究

目的 设计、合成一系列 8-氟-2,3-二氢喹啉-4(1H)-酮缩氨基脲类化合物,测定其体外抗真菌活性。方法 以邻氟苯胺为起始原料,经与丙烯酸加成、在多聚磷酸（PPA）中环合制得中间体8-氟-2,3-二氢喹啉-4(1H)-酮;该中间体与各种 N⁴-取代的氨基脲缩合得到目标化合物。采用二倍浓度稀释法测试各目标化合物的体外抗真菌活性,实验选用 8 种临床上常用的致病真菌为测试菌株,以氟康唑、伊曲康唑为阳性对照药。结果与结论 16 个 8-氟-2,3-二氢喹啉-4(1H)-酮缩氨基脲类化合物均未见文献报道,其结构经¹H-NMR、MS 谱确证;活性测试结果表明,合成的多个目标化合物对测试真菌表现出较好的体外抑菌活性,尤其是对红色毛藓菌的活性均好于阳性对照药。     

3-苯甲酰基-2H-1-苯并吡喃-2-酮衍生物的设计、合成及抗肿瘤活性

目的 设计合成3-苯甲酰基-2H-1-苯并吡喃-2-酮衍生物,并评价其抗肿瘤活性。方法 以取代苯乙酮为原料,首先与碳酸二乙酯经Claisen缩合得到相应的取代β-酮酸酯,再与取代水杨醛经Knoevenagel缩合,同时环合得到目标化合物。采用人急性早幼粒白血病细胞HL-60及人乳腺癌细胞T47D对部分目标化合物的抗肿瘤活性进行初步评价。结果 合成了18个目标化合物,其中13个未见文献报道,目标化合物的结构经核磁共振氢谱和红外光谱确证。化合物III₁₅对人乳腺癌细胞T47D的抑制活性较强,IC₅₀值为38 μmol.L^-1;化合物III₁、III₂、III₁₅对人急性早幼粒白血病细胞HL-60的抑制活性较好,IC₅₀值分别为37、36、16 μmol.L^-1。结论 3-苯甲酰基-2H-1-苯并吡喃-2-酮衍生物作为新型肿瘤抑制剂,其构效关系值得进一步研究。     

N-（氨基吡啶）苯甲酰胺类组蛋白去乙酰化酶抑制剂的合成及其抗肿瘤活性研究

目的 寻找新型组蛋白去乙酰化酶（HDACs）抑制剂,探讨其初步构效关系。方法 在前期研究发现活性结构 Ａ和Ｂ的基础上,参考恩替司他（MS-275）的结构特点,设计合成系列N-（氨基吡啶）苯甲酰胺类新化合物。采用苯并三氮唑-N,N,N',N’-四甲基脲六氟磷酸盐(HBTU)为缩合剂,以取代羧酸与2,3-二氨基吡啶或3, 4-二氨基吡啶反应生成系列含N-（氨基吡啶）结构的目标化合物;采用CCK-8 法并进行体外组蛋白去乙酰化酶抑制活性及抗肿瘤细胞增殖活性测试。 结果 共合成 18 个未见文献报道的新化合物,其结构经质谱、核磁共振氢谱确认。体外抗肿瘤初步研究表明：所有目标化合物均具有组蛋白去乙酰化酶抑制活性及抗肿瘤细胞增殖活性,Ⅴ-12、Ⅴ-13 和Ⅴ-16等化合物体外抑酶活性和抗肿瘤活性与阳性对照药MS-275相当,值得进一步深入研究。结论 初步构效关系研究发现,含有活性结构B的化合物具有更好的体外抗肿瘤活性;适当增加化合物酶表面识别区基团（R基团）的空间位阻或在R基团上引入供电子取代基将会增强化合物的抗肿瘤活性。     

多羟基苯甲醛席夫碱的合成及其 α-葡萄糖苷酶抑制活性

目的 设计合成系列多羟基苯甲醛席夫碱,初步测定其对 α-葡萄糖苷酶的抑制活性。方法 以羟基取代苯甲醛及芳香胺为原料,采用微波辅助合成法合成多羟基苯甲醛席夫碱,并对目标化合物进行α-葡萄糖苷酶抑制活性实验。结果 合成了18个目标化合物,其结构均经红外光谱及核磁共振氢谱确证,化合物2、3、4、8、13、14、15、16为已知化合物,其余 10 个化合物为新化合物。结论 所合成的目标化合物具有较强的α-葡萄糖苷酶抑制活性,其中3-羟基苯胺-3,4-二羟基苯甲醛席夫碱(10)、3-羟基苯胺-2,4,6-三羟基苯甲醛席夫碱(12)、苯胺-2,4-二羟基苯甲醛席夫碱(15)的α-葡萄糖苷酶抑制活性均强于参照物白藜芦醇（IC₅₀=23.9 μmol·L^-1）,它们的IC₅₀值分别为 8.93、4.69、8.59 μmol·L^-1。酶抑制动力学实验表明该系列化合物为α-葡萄糖苷酶的非竞争性抑制剂。     

新型乙酰胆碱酯酶抑制剂5H-噻唑并[3,2-a]嘧啶类化合物的设计、合成与生物活性研究

目的 寻找作为乙酰胆碱酯酶抑制剂的具有新化学结构类型的化合物。方法 采用分子对接的虚拟筛选方法寻找新型乙酰胆碱酯酶抑制剂，设计了10个5H-噻唑并[3,2-a]嘧啶类化合物。以芳醛、硫脲等为起始原料，通过Biginelli反应生成二氢嘧啶类化合物，再与氯代苯乙酮作用经Hantzsch环合反应制得目标化合物，其结构经红外光谱、质谱、核磁共振氢谱和碳谱确证。采用Ellman方法进行体外抑制乙酰胆碱酯酶活性测试。 结果 合成了10个5H-噻唑并[3,2-a]嘧啶类化合物，体外抑制乙酰胆碱酯酶活性测试结果显示，所有目标化合物均具有乙酰胆碱酯酶抑制活性，其中3个目标化合物在10 μmol.L^-1时抑制活性均超过50%。结论5H-噻唑并[3,2-a]嘧啶类化合物是潜在的乙酰胆碱酯酶抑制剂。将计算机辅助药物分子设计、有机合成和生物活性测试相结合是发现和设计新型乙酰胆碱酯酶抑制剂的有效途径。     

2,2-二甲基苯并吡喃类衍生物的合成

目的 设计合成一系列苯并吡喃类衍生物。方法 以2-甲基-丁-3-炔-2-醇为起始原料,经氯代、Williamson 成醚、环合、Aldol 缩合4步反应得到目标化合物。结果与结论 合成了16个未见文献报道的新化合物,其结构经¹H-NMR 和 MS 谱确定。所有目标化合物的抗肿瘤活性测试正在进行中。     

L-异谷氨酰胺类氨肽酶N抑制剂的合成及初步活性

目的 设计并合成一系列新型L-异谷氨酰胺类衍生物,并测定其对氨肽酶N (APN)的抑制活性。方法 以L-谷氨酸为基本骨架,与3,4-二氯苯甲酸形成酰氯发生酰化、环合反应得到关键中间体环状酸酐,再经氨解反应合成目标化合物。采用体外抑酶试验测定化合物抑制氨肽酶N的活性。 结果与结论 合成了15个未见报道的L-异谷氨酰胺衍生物,其结构经过¹H-NMR、MS、和IR的确证。其中化合物I₄、I₆显示出较好的抑制氨肽酶N活性(IC₅₀=20~40 μmol.L^-1),有进一步研究的价值。     

3-取代苯甲酰基-4H-色烯-4-酮的合成及其抗快速增殖分枝杆菌活性研究

目的 设计合成3-苯甲酰基-4H-色烯-4-酮类化合物,并测定其体外抗快速增殖分枝杆菌活性。 方法 以焦性没食子酸和取代苯甲酸为原料,经Friedel-Crafts酰基化、Baker-Venkataraman重排等反应合成目标化合物,初步测定了目标化合物的抗快速增殖分枝杆菌活性。结果 共合成8个3-苯甲酰基-4H-色烯-4-酮类化合物,其结构经核磁共振氢谱和质谱确证。化合物2a、2e呈现边缘抗快速增殖分枝杆菌活性。结论 在具有抗快速增殖分枝杆菌活性的天然产物(S)-3-(4-甲氧苄基)-7,8-亚甲二氧基二氢高异黄酮的2,3-位引入双键、7,8-位更换为甲氧基以及9位以羰基替代亚甲基均会导致抗快速增殖分枝杆菌活性的大幅降低。     

1-苯氨基-5H-哒嗪并[4,5-b]吲哚类化合物的设计、合成及体外抗肿瘤活性

目的设计并合成1-苯氨基-5H-哒嗪并[4,5-b]吲哚类化合物,评价其抗肿瘤活性。方法以5-乙酰氧基-6-溴-2-溴甲基-1-环丙基-1H-吲哚-3-羧酸乙酯为起始原料,经多步反应合成目标化合物。采用MTT法,gefitinib为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物抗肿瘤活性进行进行检测。结果合成了8个未见文献报道的新化合物,其结构经1H-NMR和MS确证。体外活性实验表明：多种化合物显示良好的抗肿瘤活性,其中化合物10f对Bel-7402和HT-1080肿瘤细胞株的抑制作用分别是阳性对照药gefitinib的6倍和7倍。结论1-苯氨基的苯环上的取代基和1-苯氨基-5H-哒嗪并[4,5-b]吲哚的8位引入的3-[[5-（脂肪（环）胺甲基）呋喃-2-基]甲硫基]丙氧基中脂肪（环）氨的种类均显著影响化合物的活性。     

Selective thromboxane synthetase inhibitors and antihypertensive agents. New derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole, 4-hydrazinopyridazino[4,5-a]indole, and related compounds

A series of new derivatives of 4-hydrazino-5H-pyridazino[4,5-b]indole (5) and 4-hydrazinopyridazino[4,5-a]indole (12) have been synthesized to investigate their activities as selective thromboxane synthetase inhibitors as well as antihypertensive agents. Several of the prepared compounds were found to be selective thromboxane synthetase inhibitors, in concordance with the Gorman model. The most potent were 8-(benzyloxy)-3,4-dihydro-4-oxo-5H-pyridazino[4,5-b]indole (3c) and 8-methoxy-4-hydrazino-5H-pyridazino[4,5-b]indole (5). This last compound did not inhibit prostacyclin formation and showed an antihypertensive activity similar to that of hydralazine. The acute toxicity in mice for 5a . HCl is about 2.2 times less than that for hydralazine.     

1-苯胺基-5H-哒嗪并[4,5-b]吲哚类化合物的合成及体外抗肿瘤活性

目的设计并合成1-苯胺基-5H-哒嗪并[4,5-b]吲哚类化合物,评价其体外抗肿瘤活性。方法以5-乙酰氧基-6-溴-2-溴甲基-1-环丙基-1H-吲哚-3-羧酸乙酯为起始原料,经8～9步反应合成目标化合物;采用MTT法,测定了目标化合物对肿瘤细胞株Bel-7402和HT-1080的抑制活性。结果与结论合成了12个新化合物,其结构经1H-NMR和MS确证;多个化合物显示出良好的抗肿瘤活性,化合物10a和10d活性突出,对肿瘤细胞株Bel-7402和HT-1080的抑制活性分别是阳性对照药gefitinib的4倍和5倍,值得进一步研究。     

New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.

Some fused 5H-pyridazino[4,5-b]indoles (7-10), substituted in positions 1 and 4 by hydrazine and/or amino groups, have been synthesized. These new compounds present a planar topography, a dipole with an adjacent acidic proton, and a basic hydrogen-acceptor site opposite the dipole. These compounds have some resemblance to carbazeram and other pyridazino agents with cardiotonic activity. Some of the new compounds here described possess inotropic activity (Table I and II), with a complementary effect as inhibitors of platelet aggregation (Table III and IV). 1-Hydrazino-4-(3,5-dimethyl)-1-pyrazolyl-5H-pyridazino[4,5-b ]indole hydrochloride (7a.HCl) is the first compound described in the literature with activities as inhibitor of PDE-IV and as selective inhibitor of TXA2 synthetase (Table V).     

Synthesis and biological activity of functionalized indole-2-carboxylates, triazino- and pyridazino-indoles

Condensation of aryl hydrazines with ethyl pyruvate gave the respective hydrazones 4-6; Fischer indolization led to substituted-1H-indole-2-carboxylic acid ethyl esters 7-9. The Mannich reaction of these compounds with formaldehyde and morpholine yielded ethyl 3-(morpholinomethyl)-substituted-1H-indole-2-carboxylates 10-12. The 5,7-dichloro-1H-indole-2-carbohydrazide 13 was cyclized with methyl orthoformate in DMF to give 6,8-dichloro[1,2,4]triazino[4,5-a]indol-1(2H)-one 14. Vilsmeier-Haack formylation of 7-9 gave ethyl 3-formyl-substituted-1H-indole-2-carboxylates 15-17 whose 2,2'-((5-chloro-2-(ethoxycarbonyl)-1H-indol-3-yl)methylene)bis-(sulfanediyl) diacetic acid 18 was prepared. The reaction of 15 and 16 with substituted anilines by conventional and microwave methods gave ethyl 3-(N-aryliminomethyl)-5-halo-1H-indole-2-carboxylates 19-29. In a cyclocondensation reaction of 19-25 with thiolactic acid or thioglycolic acid substituted indolylthiazolidinones 30-33 were prepared. Reaction of hydrazine hydrate with 15-17 did not give the respective hydrazones but directly led to the cyclized products substituted-3H-pyridazino[4,5-b]indol-4(5H)-ones 34-36, while a reaction with 2,4-dichlorophenylhydrazine yielded the uncyclized hydrazones. The chlorination of 35 and 36 with POCl3 gave pyridazino[4,5-b]indoles 39 and 40, respectively; reaction of the latter compounds with morpholine gave 4-(substituted-5H-pyridazino[4,5-b]indol-4-yl)morpholine 41 and 42. Mannich reaction of 34 with formaldehyde and N-ethylpiperazine gave 8-chloro-3-((4-ethylpiperazin-1-yl)methyl)-3H-pyridazino[4,5-b]indol-4(5H)-one 43. The microwave assistance of selected reactions has a profound effect on the reaction speed. The structures of the new compounds were confirmed by both analytical and spectral data. Some compounds were subjected to investigations concerning their antimicrobial, tranquilizing, and anticonvulsant activities.     

Chemical and pharmacological investigations on 2H-pyridazino[4,5-b] [1,4]benzothiazin-1(10H)-one derivatives

The methylation of 2H-pyridazino [4,5-b][1,4]benzothiazin-1(10H)-one-5,5-dioxide 2 and the oxidation of 2-methyl-2H-pyridazino[4,5-b][1,4]benzothiazin-1(10H)-one 3 produced the same compound 4. On the contrary, in the 2-dialkylaminoalkylic series, the dialkylamino-alkylation and the oxidation reactions, carried out on compounds 2 and 8 respectively, afforded derivatives 7 and 9. In addition, the behaviour to the oxidation of the corresponding 10-methyl and 10-dialkylaminoalkyl analogues is also described. The synthesized compounds were tested for their analgesic, antiexudative and anti-inflammatory activities. The pharmacological results showed that in general dialkylaminoalkyl derivatives are more active than methyl derivatives. In particular, compounds 7 b, 9 b and 11 c exhibited an analgesic activity comparable to that of phenylbutazone; moreover 10-substituted compounds 11 a, 11 b and 11 c, screened p.o. as anti-inflammatory agents in rats, resulted equipotent to phenylbutazone and more active than 2-substituted isomers. These activities are coupled with a high LD50 and a very low ulcerogenic potential.     

Selenium-containing heterocycles: synthesis and pharmacological activities of some new 4-methylquinoline-2(1H) selenone derivatives

Several selenolo[2,3-b]quinolines and pyrimido[4',5':4,5]selenolo[2,3-b]quinolines were prepared by annulations via reaction of NaSeH with 2-chloro-3-cyano-4-methylquinoline 1 followed by reactions with aromatic aldehydes, cycloalkanones, and acetic anhydride. Spectroscopic (IR, 1H-NMR, and MS) properties of the synthesized compounds are reported. Some selected compounds 5a, 7b, 7c, 8b-d, 9a, 11b, and 11d were investigated for their anti-inflammatory and analgesic activities; in addition, the most active compounds were tested for their ulcerogenicity and acute toxicity. Moreover, some of the test compounds 7c, 9a, 11b, and 11d were screened for their antibacterial and antifungal activities.     

Synthesis and benzodiazepine receptor binding studies of pyridazino[3,4-b]indoles]

A series of methyl 9H-pyridazino[3,4-b]indole-3-carboxylates and related compounds were synthesized using a Diels-Alder reaction of methyl 3-(1H-indol-3-yl)-2-propenoates and dibenzyl azodicarboxylate. Several compounds were found to have high affinity for the benzodiazepine receptor. Their structure-activity relationships are discussed.     

Synthesis and anti-tumor activities of a novel series of tricyclic 1-anilino-5H-pyridazino[4,5-b]indoles

A novel series of 1-anilino-5H-pyridazino[4,5-b]indoles was designed and synthesized in order to find novel potent anti-tumor compounds. Their structures were confirmed by MS, (1)H-NMR, and elemental analysis. All compounds were screened for their cytotoxic activity against two human cancer cell lines (Bel-7420, HT-1080). The compounds 8, 9, and 17 showed 50% growth inhibitory activity in low micromolar concentration (IC(50 )= 7.7 approximately 12.8 microM). Among them, compound 17 displayed the most potent anti-tumor activity with IC(50) values of 8.2 microM and 7.9 microM against Bel-7402 and HT-1080, respectively.